Moderna’s mRNA Flu Shot Gets Major Boost

Moderna’s mRNA flu shot, mFlusiva, is poised to hit the market after an FDA advisory panel unanimously endorsed it for those 50 and older, praising its faster-response potential against evolving flu strains. While the panel’s vote is a major win, the FDA hasn’t yet finalized approval—no permanent vaccine chief is in place—and the CDC’s advisory committee faces legal hurdles. This mRNA approach could revolutionize flu preparedness, unlike traditional vaccines that rely on outdated strain predictions. The approval process nearly stalled in February, sparking debate over FDA’s stance on mRNA tech, but Moderna pushed through. Final decisions from both agencies are still pending—watch this space. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/78bc3929b701c576